CP05 peptide

CP05 peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-CRHSQMTVTSRL-OH

H-Cys-Arg-His-Ser-Gln-Met-Thr-Val-Thr-Ser-Arg-Leu-OH

12

95.02%

C₅₆H₉₉N₂₁O₁₈S₂

1418.66

Synthetic

Powder

CP05 is an exosomal capture peptide, and can recognize and capture exosomal marker CD63 specifically. It is used in the construction of fusion peptides for the delivery of exosomes in bone regeneration. The fusion peptides are designed by connecting collagen-binding domains (CBDs) of collagen type I/III with exosomal capture peptides CP05 directly or via rigid linkers (EAAAK).

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Ma S, Wu J, Hu H, Mu Y, Zhang L, Zhao Y, Bian X, Jing W, Wei P, Zhao B, Deng J, Liu Z. Novel fusion peptides deliver exosomes to modify injectable thermo-sensitive hydrogels for bone regeneration. Mater Today Bio. 2021 Dec 27;13:100195. doi: 10.1016/j.mtbio.2021.100195. PMID: 35024598; PMCID: PMC8724941.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.